| MET |
Report |
Operating EPS |
IN-LINE |
pred ~$2.32 vs. cons $2.339 |
MEDIUM |
| MET |
Report |
Variable investment income |
MISS |
pred ~$245M vs. cons $267.9M |
HIGH |
| MET |
Report |
Group Benefits interest-adjusted benefit ratio |
IN-LINE |
pred ~75.0% vs. cons 74.3% |
MEDIUM |
| MET |
Guide |
FY26 VII |
UNCHANGED |
guide ~$1.6B vs. cons $1.590B |
HIGH |
| MET |
Guide |
FY26 RIS adjusted earnings |
UNCHANGED |
guide $1.6B-$1.8B vs. cons UNVERIFIED |
LOW |
| MET |
Guide |
Group Benefits 2H non-medical health trend |
UNCHANGED |
guide moderation vs. cons UNVERIFIED |
LOW |
| MET |
Guide |
3Q VII commentary |
UNCHANGED |
guide constructive backdrop vs. cons UNVERIFIED |
LOW |
| MET |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| MET |
Return |
5-day cumulative residual |
-2.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained outlook and weak near-term VII mix should weigh on forward estimates |
LOW |